BOLD-100,即反式四氯二(1H-吲唑)合钌(III)酸钠,是一种临床开发中的钌基的抗癌药。截至2021年11月,在晚期胃肠道癌患者中,BOLD-100正与化疗方案FOLFOX英语FOLFOX联合进行1b期临床试验。[1]它由Bold治疗有限公司开发。[2]

BOLD-100
BOLD-100 Chemical Structure
临床资料
给药途径Intravenous
识别信息
  • sodium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)]
CAS号197723-00-5
PubChem CID
DrugBank
ChEBI
化学信息
3D模型(JSmol英语JSmol
  • C1=CC=C2C(=C1)C=NN2.C1=CC=C2C(=C1)C=NN2.[Na+].Cl[Ru](Cl)(Cl)Cl
  • InChI=1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+4/p-4
  • Key:YGDDGJPSWMFECS-UHFFFAOYSA-J

BOLD-100具有八面体结构,赤面上由两个反式吲唑配体和四个氯离子配体,它的阳离子,且含有痕量的[3]

参考文献

编辑
  1. ^ U.S. National Library of Medicine. (2020). BOLD-100 in combination with FOLFOX for the treatment of advanced solid tumours. https://clinicaltrials.gov/ct2/show/NCT04421820页面存档备份,存于互联网档案馆
  2. ^ Bold Therapeutics. (2021). Technology. https://www.bold-therapeutics.com/technology页面存档备份,存于互联网档案馆
  3. ^ Vojkovsky, T., Sill, K., Carie, A. (2018). Manufacture of trans-[tetrachlorobis(1H-inadazole)ruthenate(III)] and compositions thereof (U.S. Patent No. 10, 611,787). U.S. Patent and Trademark Office. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&f=G&l=50&d=PTXT&S1=10,611,787&OS=10,611,787&RS=10,611,787[失效链接])

参见

编辑